An integrated experimental and deep learning pipeline reveals cell-level targeting of nanocarriers in whole bodies.

Lipid nanocarriers can be used to modulate release of multiple endogenous hormones from the enteroendocrine system.

An integrated experimental and deep learning pipeline reveals cell-level targeting of nanocarriers in whole bodies.

Polymer-based drug delivery systems can effectively overcome the limitations of free drugs in terms of solubility, stability, and plasma half-life, yet their development has traditionally relied on t...

The LMU pharmaceutical scientist has been awarded a fourth grant by the European Research Council (ERC) to test a new platform for nanocarriers of RNA therapeutics.

Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects. Targeted drug delivery using nanocarriers has demonstrated potential for overcoming these limitations. The critical bottleneck limiting the development of beta cell-targeted therapies is a lack of highly specific beta cell markers. This review provides an overview of the use of nanocarriers for cell-targeted delivery and the current state of the field of beta cell targeting. Technologies such as systematic evolution of ligands by exponential enrichment (SELEX) aptamer selection, phage display screening, and omics datasets from human samples are highlighted as tools to identify novel beta cell-specific targets that can be combined with nanocarriers for targeted delivery of therapeutics. Ultimately, beta cell-targeted therapies using nanocarriers present a unique opportunity to develop tailored treatments for each stage of type 1 diabetes with the goal of providing individuals with treatment options that prevent further progression or reverse the course of the disease. Graphical Abstract

In the field of nano-bio interactions, the cellular uptake of nanocarriers and the modulating factors, e.g. the presence of a protein shell - the prot…

Targeted drug delivery to tumors is crucial for effective and safe treatment of cancer. In a recent breakthrough, researchers from Okayama University have developed a pH-responsive nanomaterial using ...

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long...

Seed priming, which represents a pre-sowing treatment that improves seed performance, can be further optimized with the use of advanced nanomaterials and i

Novel hybrid polymer nanocarriers enable effective vaccine delivery in the lungs and the targeted activation of immune cells.

The European Research Council (ERC) has today announced the first group of researchers to be awarded ERC Proof of Concept Grants in 2025. In this initial round of the 2025 competition, 150 projects wi...

MOFs, a class of crystalline hybrid materials composed of metal ion clusters coordinated to organic ligands, was chosen as the nanoparticle core of SENDS due to their exceptionally high surface areas, tunable pore sizes, and chemical versatility, rendering them a...

Read the full paper: Macrophage-Targeted Nanocarriers Based on Tetrahedral DNA Nanostructure Alleviate Sepsis-Induced Acute Lung Injury by Triple-Pathway Suppression of Pyroptosis

Cancer is one of the leading causes of death worldwide and represents a significant burden on global health systems. Many existing chemotherapy treatments come with severe side effects, ranging from h...